Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Clinical Study Evaluating the Safety, Efficacy, Tolerability, and Pharmacokinetics of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy

NCT07468851 is registered in ClinicalTrials.gov with Jiangsu Hansoh Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07468851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07468851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Clinical Study Evaluating the Safety, Efficacy, Tolerability, and Pharmacokinetics of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy
Lead sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 5, 2026
Completion date
April 30, 2029
Enrollment
180 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk non-muscle-invasive bladder cancer